Age: 72.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Guillain-Barre syndrome
Clinical narrative: PARALYZED FROM NECK DOWN; CAN NOT SPEAK; ON VENTILATOR; ENCEPHALOPATHY; RESPIRATORY FAILURE; PNEUMONIA; AFFIBRILATION; GUILLAIN-BARRE SYNDROME; NAUSEA; TACHYCARDIA; DIZZINESS; BACK PAIN; LEG PAIN; This spontaneous report received from a consumer and concerned a 72 year old female. The patient's weight was 110 pounds, and height was 64 inches. The patient's concurrent conditions included mild cognitive impairment, non-smoker, and abstains from alcohol, and other pre-existing medical conditions included patient had no known drug allergies or history of drug abuse or illicit drug use.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805022, and expiry: 25-MAY-2021) dose was not reported, administered on 06-MAR-2021 09:30 for prophylactic vaccination. Concomitant medications included vitamins NOS (not otherwise specified) for mild cognitive impairment.  On 17-MAR-2021, the patient developed Guillain-Barre syndrome and was hospitalized. On 17-MAR-2021, the patient experienced a fibrillation (PT of atrial fibrillation), nausea and non-serious events of tachycardia, dizziness, back pain, leg pain.  On 20-MAR-2021, the patient experienced respiratory failure, encephalopathy and pneumonia.  On 22-MAR-2021, the patient was placed on ventilator. On 22-MAR-2021, the patient experienced can not speak.  On 24-MAR-2021, the patient was paralyzed from neck down. On 26-MAR-2021, the patient was in neuro intensive care unit. The discharge date was not provided. On unspecified date, laboratory and diagnostic tests included: CAT scan and multiple MRI's with no result provided. Treatment medications (dates unspecified) included: plasma. The patient recovered from pneumonia on 27-MAR-2021, was recovering from a fibrillation, and tachycardia, had not recovered from Guillain-Barre syndrome, paralyzed from neck down, can not speak, on ventilator, and respiratory failure, and the outcome of nausea, dizziness, leg pain, back pain and encephalopathy was not reported. This report was serious (Hospitalization Caused / Prolonged, and Life Threatening).; Sender's Comments: v0 A 72-year-old female patient with a mild cognitive impairment, non-smoker, abstains from alcohol, and no known drug allergies or history of drug abuse or illicit drug use experienced "affibrilation", tachycardia, back pain, leg pain, dizziness, nausea approximately week and a half after receiving Janssen COVID-19 Vaccine Ad26.COV2.S. Three days later the patient experienced encephalopathy, pneumonia. and the next day the patient experienced respiratory failure, could not speak and was kept on ventilator. Four days later the patient was paralyzed from neck down and was diagnosed with Guillain-Barre syndrome. She had received plasma transfusion 4 times. On an unknown date, patient underwent multiple lab test and was given multiple drugs. On an unknown date, patient underwent CAT and MRI multiple times, but the results were unknown. This case has insufficient information to make a meaningful medical assessment. Additional information has been requested.